Menu

AACR Apologizes for Delays in Retracting Papers

Nine of the most recent retractions from AACR journals are for papers coauthored by embattled cancer researcher Bharat Aggarwal.

Sep 5, 2018
Catherine Offord

Much of Aggarwal’s research focused on potential anticancer effects of curcumin, a chemical found in turmeric.
WIKIMEDIA, SIMON A EUGSTER 

The American Association for Cancer Research has issued retractions, corrections, or editor’s notes for a handful papers across five of its journals and is sorry for the time it’s taken to do so, according to a statement published yesterday (September 4) in Cancer Research. Nine of those retractions relate to papers coauthored by cancer researcher Bharat Aggarwal, formerly of the University of Texas’s MD Anderson Cancer Center, Retraction Watch reports.

“Unfortunately, we have been delayed in correcting the published record, and for this we apologize,” the statement reads. “We have significantly improved our procedures and processes so that, going forward, we can make these corrections to the published record in a more timely manner.”

See “More Retractions for Cancer Researcher

MD Anderson began an investigation into Aggarwal’s work in 2012; numerous papers by Aggarwal have since been retracted from journals including the Journal of Biological Chemistry and Molecular Pharmacology. Including the latest nine reports, Aggarwal—who retired from his post in 2015—has now clocked a total of 28 retractions. Eight more of his papers in AACR journals will have an editor’s note appended to them, according to Retraction Watch.

See “Seven More Retractions for Cancer Researcher

It’s not the first time AACR has dragged its feet removing papers from the literature. In July, Retraction Watch reported that several articles containing image manipulation by cancer researcher Anil Jaiswal were still available in three of AACR’s journals—nearly two years after his institution, the University of Maryland, had requested their retraction.

See “The Zombie Literature

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.